Showing results (1191-1200 of 2,755) with videos related to
Sort By:
Pageof 276
Pharmacogenomics|November 23, 2012
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patientsMariana Rieck, Artur F Schumacher-Schuh, Vivian Altmann, et al.Pharmacogenomics|October 11, 2014
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposureJackson K Mukonzo, Sarah Nanzigu, Paul Waako, et al.Pharmacogenomics|October 11, 2014
Targeting pathways downstream of KRAS in lung adenocarcinomaZehua Zhu, Hadrien G Golay, David A BarbiePharmacogenomics|August 2, 2014
Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experimentsKenneth K W To, Miao Hu, Brian TomlinsonPharmacogenomics|November 7, 2013
Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP studyKei Kamide, Kei Asayama, Tomohiro Katsuya, et al.Pharmacogenomics|November 7, 2013
ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patientsXiaoye Huang, Tao Yu, Xin Li, et al.Pharmacogenomics|November 7, 2013
Genetic variations of human CYP2D6 in the Chinese Han populationJian-Chang Qian, Xin-Min Xu, Guo-Xin Hu, et al.Pharmacogenomics|November 7, 2013
Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regionsChiho Ono, Hironori Kikkawa, Akiyuki Suzuki, et al.Pharmacogenomics|November 7, 2013
Pregnancy and pharmacogenomics in the context of drug metabolism and responseAnders Helldén, Parvaz MadadiPharmacogenomics|November 7, 2013
Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathwayFrancisca Dias, Ana L Teixeira, Juliana I Santos, et al.Pageof 276